F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
Alberto Chiappori,Gerold Bepler,Fabrice Barlesi,Jean-Charles Soria,Martin Reck,Alessandra Bearz,Fernando Barata,Giorgio V. Scagliotti,Keunchil Park,Asavari Wagle,Astra M. Liepa,Yan D. Zhao,Nadia Chouaki,Neill Iscoe,Joachim von Pawel +14 more
TL;DR: The combination regimen of enzastaurin and pemetrexed is well tolerated but does not improve efficacy over pemetrezed and placebo as second-line treatment of unselected patients with advanced non-small cell lung cancer.
Journal ArticleDOI
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer
David R. Gandara,Natasha B. Leighl,Jean Pierre Delord,Fabrice Barlesi,Jaafar Bennouna,G. Zalcman,Jeffrey R. Infante,Karen L. Reckamp,Karen Kelly,Frances A. Shepherd,Julien Mazieres,Filip Janku,Olivia Gardner,Bijoyesh Mookerjee,Yuehui Wu,Donna S. Cox,Dan Schramek,Vijay Gopal Reddy Peddareddigari,Yuan Liu,Anthony D'Amelio,George R. Blumenschein +20 more
TL;DR: Clinical activity exceeding the ORRs previously reported with docetaxel or pemetrexed alone in KRAS‐mutated NSCLC and meeting prespecified criteria was observed.
Journal ArticleDOI
Metronomics chemotherapy: time for computational decision support.
Dominique Barbolosi,Joseph Ciccolini,Christophe Meille,X. Elharrar,Christian Faivre,Bruno Lacarelle,Nicolas André,Fabrice Barlesi +7 more
TL;DR: This review covers the latest clinical trials investigating on metronomic vinorelbine and proposes alternative strategies for developing computational decision support to make metronomics a scientific-grounded strategy, rather than an empirical practice at the bedside.
Journal ArticleDOI
Preoperative psychological global well being index (PGWBI) predicts postoperative quality of life for patients with non-small cell lung cancer managed with thoracic surgery.
Fabrice Barlesi,Christophe Doddoli,Anderson Loundou,Elodie Pillet,Pascal Thomas,Pascal Auquier +5 more
TL;DR: A simple assessment of patients at higher risk of a poor short-term postoperative QOL could be easily performed preoperatively, taking into account certain socio-demographic factors and the results of the QOL assessment using the PGWBI.
Journal ArticleDOI
Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses.
Hossein Borghaei,Julie R. Brahmer,Leora Horn,Neal Ready,Martin Steins,Enriqueta Felip,Luis Paz-Ares,Oscar Arrieta,Fabrice Barlesi,Scott J. Antonia,Jérôme Fayette,Naiyer A. Rizvi,Lucio Crinò,Martin Reck,Wilfried Eberhardt,Matthew D. Hellmann,Kaushal Desai,Ang Li,Diane Healey,David R. Spigel +19 more
TL;DR: Nivo, afully human IgG4 programmed death-1 immune checkpoint inhibitor, is approved in the US for pts with previously treated metastatic NSCLC and in the EU for pretreated locally advanced or metastatic squamousNSCLC, based on results of 2 ph III trials.